Filter Results:
(61)
Show Results For
- All HBS Web
(61)
- News (15)
- Research (32)
- Multimedia (1)
- Faculty Publications (21)
Show Results For
- All HBS Web
(61)
- News (15)
- Research (32)
- Multimedia (1)
- Faculty Publications (21)
Page 1 of 61
Results →
- Article
Missing the Near Miss: Recognizing Valuable Learning Opportunities in Radiation Oncology
By: Palak Kundu, Olivia Jung, Luca F. Valle, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow
“Near miss” events are valuable low-cost learning opportunities in radiation oncology as they do not result in patient harm and are more pervasive than adverse events that do. Near misses vary depending on the presence of a latent error of behavior or process, and the... View Details
Kundu, Palak, Olivia Jung, Luca F. Valle, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg, and Ann Raldow. "Missing the Near Miss: Recognizing Valuable Learning Opportunities in Radiation Oncology." Practical Radiation Oncology 11, no. 3 (May 2021): e256–e262.
- Awards
Exceptional Women in Oncology Award
Winner of the 2017 Exceptional Women in Oncology Award for Advocacy from the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) Education. View Details
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- Article
Psychological Safety and Near Miss Events in Radiation Oncology
By: Palak Kundu, Olivia Jung, Kathy Rose, Chonlawan Khaothiemsang, Nzhde Agazaryan, Amy C. Edmondson, Michael L. Steinberg and Ann C. Raldow
Background: Near miss events, defined as harm averted due to chance, are learning opportunities in radiation oncology. Psychological safety is a feature of a learning environment characterized by interpersonal risk taking. We examine the effects of near miss type and... View Details
Kundu, Palak, Olivia Jung, Kathy Rose, Chonlawan Khaothiemsang, Nzhde Agazaryan, Amy C. Edmondson, Michael L. Steinberg, and Ann C. Raldow. "Psychological Safety and Near Miss Events in Radiation Oncology." Journal of Clinical Oncology 37, no. 27 suppl. (September 20, 2019): 231.
- Article
Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology
By: Palak Kundu, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg and Ann Raldow
Background
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Psychological safety, a shared belief that interpersonal risk taking is safe, is an important determinant of incident reporting. However, how psychological safety affects near-miss reporting is unclear, as near misses contain contrasting cues that... View Details
Kundu, Palak, Olivia Jung, Amy C. Edmondson, Nzhde Agazaryan, John Hegde, Michael Steinberg, and Ann Raldow. "Resilience vs. Vulnerability: Psychological Safety and Reporting of Near Misses with Varying Proximity to Harm in Radiation Oncology." Joint Commission Journal on Quality and Patient Safety 47, no. 1 (January 2021): 15–22.
- November 12, 2018
- Article
Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology
By: Richard G. Hamermesh and Kathy Giusti
Hamermesh, Richard G., and Kathy Giusti. "Precision Medicine Has Transformed Cancer Treatment. Here's How to Move It Beyond Oncology." Fortune.com (November 12, 2018).
- September 2016
- Article
Value Based Care and Bundled Payments: Anesthesia Care Costs for Outpatient Oncology Surgery Using Time-driven Activity-based Costing
By: Katy E. French, Alexis B. Guzman, Augustin C. Rubio, John C. Frenzel and Thomas Feeley
Background:
With the movement towards bundled payments, stakeholders should know the true cost of the care they deliver. Time-driven activity-based costing (TDABC) can be used to estimate costs for each episode of care. In this analysis, TDABC is used to both... View Details
French, Katy E., Alexis B. Guzman, Augustin C. Rubio, John C. Frenzel, and Thomas Feeley. "Value Based Care and Bundled Payments: Anesthesia Care Costs for Outpatient Oncology Surgery Using Time-driven Activity-based Costing." Healthcare: The Journal of Delivery Science and Innovation 4, no. 3 (September 2016): 173–180.
- September 2012
- Supplement
Intraoperative Radiotherapy for Breast Cancer (B)
By: Willy Shih
The intraoperative radiotherapy (IORT) business at Carl Zeiss Meditec had struggled with growth since the time of the (A) case. Though the unit had grown revenues in excess of 50% and had exceeded its EBIT target, it faced several key strategic choices. Should it... View Details
Keywords: Radiotherapy; Breast Cancer; Brachytherapy; Therapeutic Radiation; Oncology; Oncology Treatment Systems; Elekta AB; Varian Medical Systems; Xoft; Electronic Brachytherapy; Intraoperative Radiotherapy; Disruptive Innovation; Health Care and Treatment; Entrepreneurship; Technological Innovation; Growth and Development Strategy; Health Industry; Germany
Shih, Willy. "Intraoperative Radiotherapy for Breast Cancer (B)." Harvard Business School Supplement 613-040, September 2012.
- May 2014
- Case
Health Care Accountability: Examples in Cancer Treatment
By: Regina E. Herzlinger and Natalie Kindred
This case is designed to support a discussion of the importance of outcomes evidence in empowering the public to make better health care decisions, the desired level of transparency and accountability for health care providers, and the issues with current measuring and... View Details
Keywords: Accountability; Health Care; Cancer; Cancer Treatment; Memorial Sloan Kettering Cancer Center; Cancer Treatment Centers Of America; Vantage Oncology; Radiology; Risk Adjustment; Treatment Outcomes; Health Care Outcomes; Prostate Cancer; Transparency; Health Care and Treatment; Risk Management; Outcome or Result; Health Industry; United States
- December 2013 (Revised February 2014)
- Supplement
Reinventing Brainlab (B)
By: Regina E. Herzlinger and Karol Misztal
The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details
Keywords: Strategy; Information Infrastructure; Applications and Software; Medical Specialties; Information Technology Industry; Health Industry; Germany
Herzlinger, Regina E., and Karol Misztal. "Reinventing Brainlab (B)." Harvard Business School Supplement 314-054, December 2013. (Revised February 2014.)
- September 2012 (Revised March 2014)
- Case
Reinventing Brainlab (A)
By: Regina E. Herzlinger, Vincent Dessain and Karol Misztal
The management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment. View Details
Keywords: Strategy; Information Infrastructure; Applications and Software; Medical Specialties; Health Care and Treatment; Information Technology Industry; Health Industry; Germany
Herzlinger, Regina E., Vincent Dessain, and Karol Misztal. "Reinventing Brainlab (A)." Harvard Business School Case 313-069, September 2012. (Revised March 2014.)
- August 2012 (Revised August 2014)
- Case
Cancer Treatment Centers of America® (A)
By: Regina E. Herzlinger and Natalie Kindred
Cancer Treatment Centers of America (CTCA), a U.S. network of four privately owned oncology focused factory hospitals, was weighing options for growth. CTCA was entirely cancer focused and specialized in treating patients with complex and advanced-stage cancers, who... View Details
Keywords: Cancer; Cancer Treatment; Health Care; Healthcare; Accountability; Outcomes; Outcomes Measurement; Outcomes Reporting; Hub And Spoke Cancer Care; Hub And Spoke; Hub-and-spoke; Focused Factory; Mission and Purpose; Private Ownership; For-Profit Firms; Health Disorders; Medical Specialties; Policy; Business Model; Expansion; Decision Choices and Conditions; Advertising; Health Care and Treatment; Innovation and Invention; Health Industry; United States
Herzlinger, Regina E., and Natalie Kindred. "Cancer Treatment Centers of America® (A)." Harvard Business School Case 313-012, August 2012. (Revised August 2014.)
- 14 Jan 2020
- Video
Meet Enrique | CORe Participant Testimonial
- December 2020 (Revised April 2021)
- Case
IBM Watson at MD Anderson Cancer Center
By: Shane Greenstein, Mel Martin and Sarkis Agaian
After discovering that their cancer diagnostic tool, designed to leverage the cloud computing power of IBM Watson, needed greater integration into the clinical processes at the MD Anderson Cancer Center, the development team had difficult choices to make. The Oncology... View Details
Keywords: Decision Making; Innovation Strategy; Knowledge Management; Knowledge Use and Leverage; Operations; Failure; Information Technology; Applications and Software; Health Care and Treatment; Product Development; Health Industry; Information Technology Industry; Technology Industry; United States; Houston; Texas
Greenstein, Shane, Mel Martin, and Sarkis Agaian. "IBM Watson at MD Anderson Cancer Center." Harvard Business School Case 621-022, December 2020. (Revised April 2021.)
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- April 2003 (Revised October 2004)
- Case
Novartis: The Challenge of Success (A)
By: Sandra J. Sucher and Stacy McManus
Preliminary results from Phase 1 clinical trials of a newly developed compound, STI571, showed that 31 out of 31 patients with chronic myelogenous leukemia (CML) had their blood counts return to normal. In the world of oncology, this was unheard of. This was the... View Details
Keywords: Decision Making; Health Testing and Trials; Innovation and Invention; Markets; Distribution; Product Development; Production; Problems and Challenges; Research; Research and Development; Complexity; Biotechnology Industry; Pharmaceutical Industry
Sucher, Sandra J., and Stacy McManus. "Novartis: The Challenge of Success (A)." Harvard Business School Case 603-043, April 2003. (Revised October 2004.)
- January 2001 (Revised July 2003)
- Case
Pharmacyclics: Financing Research & Development
By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details
Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Medical Devices and Supplies Industry; Pharmaceutical Industry; Health Industry
Baker, Malcolm P., Richard S. Ruback, and Aldo Sesia. "Pharmacyclics: Financing Research & Development." Harvard Business School Case 201-056, January 2001. (Revised July 2003.)
- January 2021 (Revised June 2021)
- Case
Hester Pharmaceuticals (A): A Pricing Dilemma
By: Dante Roscini and John Masko
In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details
Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (A): A Pricing Dilemma." Harvard Business School Case 721-001, January 2021. (Revised June 2021.)